Nebula Research & Development LLC Buys New Shares in Inspire Medical Systems, Inc. (NYSE:INSP)

Nebula Research & Development LLC acquired a new stake in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,958 shares of the company's stock, valued at approximately $548,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. First Horizon Advisors Inc. raised its holdings in Inspire Medical Systems by 885.7% in the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company's stock worth $26,000 after purchasing an additional 124 shares during the period. Huntington National Bank increased its position in shares of Inspire Medical Systems by 228.3% during the fourth quarter. Huntington National Bank now owns 174 shares of the company's stock worth $32,000 after acquiring an additional 121 shares in the last quarter. Harbour Investments Inc. raised its stake in shares of Inspire Medical Systems by 101.0% in the 4th quarter. Harbour Investments Inc. now owns 197 shares of the company's stock valued at $37,000 after purchasing an additional 99 shares during the period. AlphaQuest LLC lifted its stake in Inspire Medical Systems by 7,275.0% in the 4th quarter. AlphaQuest LLC now owns 295 shares of the company's stock valued at $55,000 after acquiring an additional 291 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its position in shares of Inspire Medical Systems by 61.9% in the fourth quarter. Quadrant Capital Group LLC now owns 327 shares of the company's stock worth $61,000 after purchasing an additional 125 shares in the last quarter. 94.91% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on INSP. Stifel Nicolaus cut their price target on shares of Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating on the stock in a research report on Monday, April 21st. Morgan Stanley cut their target price on shares of Inspire Medical Systems from $230.00 to $220.00 and set an "overweight" rating for the company in a research note on Tuesday, February 11th. Truist Financial decreased their target price on Inspire Medical Systems from $250.00 to $235.00 and set a "buy" rating on the stock in a report on Tuesday, February 11th. Robert W. Baird reduced their target price on shares of Inspire Medical Systems from $252.00 to $248.00 and set an "outperform" rating for the company in a report on Tuesday, February 11th. Finally, KeyCorp lowered their price target on shares of Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating on the stock in a report on Monday, April 21st. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $218.90.

Inspire Medical Systems Price Performance

NYSE:INSP traded down $3.27 during mid-day trading on Monday, reaching $156.54. The stock had a trading volume of 137,595 shares, compared to its average volume of 582,696. The stock has a 50-day simple moving average of $160.65 and a two-hundred day simple moving average of $179.55. Inspire Medical Systems, Inc. has a 12 month low of $123.00 and a 12 month high of $256.11. The stock has a market capitalization of $4.66 billion, a PE ratio of 90.40, a P/E/G ratio of 2.86 and a beta of 1.39.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. Equities analysts expect that Inspire Medical Systems, Inc. will post 2.16 EPS for the current year.

Insider Activity at Inspire Medical Systems

In related news, CTO John Rondoni sold 583 shares of the business's stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the transaction, the chief technology officer now owns 10,424 shares in the company, valued at $1,777,187.76. The trade was a 5.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Randy Ban sold 25,584 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $183.50, for a total value of $4,694,664.00. Following the completion of the transaction, the insider now directly owns 7,259 shares in the company, valued at $1,332,026.50. This represents a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by company insiders.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.